Cyprium joins Fortress’ growing company portfolio, which now includes nine subsidiaries focused on a broad range of disease. Fortress CEO Rosenwald aims to add one to two new companies a quarter under the Fortress umbrella.
Fortress Biotech Inc. unveiled a new subsidiary March 14, Cyprium Therapeutics, Inc. focused on treatments for the rare pediatric genetic disease Menkes disease and related copper metabolism disorders. Fortress now has nine companies under its umbrella, several of which are developing drugs for rare diseases.
Fortress, which finances each subsidiary company separately and through various means, while retaining an economic stake, has a goal of...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
